We are international

Myeloma Minute
February 4, 2016
February 4, 2016
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

This week's question: What are the best scans to monitor myeloma?

Multiple Myeloma Bone Study

New ARROW Clinical Trials: Learn How To Participate

New Selinexor STORM Clinical Trials: Learn How To Participate

New Ixazomib Clinical Trials: Learn How To Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

February 14, 2016
Race Toward a Cure with the IMF in the Skechers LA Marathon

Los Angeles, California

February 26 - February 27, 2016
Patient & Family Seminar

Boca Raton, Florida

March 5, 2016
Regional Community Workshop

Cleveland, Ohio

March 18 - March 19, 2016
Patient & Family Seminar

Seattle, Washington



Clearing the Decks for Deep Thinking Is Vital in Science

Collaboration has fueled many achievements made by the IMF and the International Myeloma Working Group (IMWG). But scientific advances also come from the kind of “deep thinking” that there is little time for in today’s hectic world. In his blog this week, IMF Chairman Dr. Brian Durie explores why both types of settings are important to push the research needle forward. To read Dr. Durie’s blog, click HERE.


European Medicines Agency Pushes for Empliciti for the Treatment of Multiple Myeloma


The Committee for Medicinal Products for Human Use (CHMP) reviewed the monoclonal antibody Empliciti® (elotuzumab) as part of the European Medicine Agency’s (EMA) accelerated assessment program. After review, CHMP recommended that Empliciti® should be used in combination with lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy. This EMA recommendation will be sent to the European Commission of the European Union, the body that will make the final decision on authorizing the marketing of Empliciti®’s use. To learn more, click HERE.


Register NOW for FREE IMF Regional Community Workshops


The IMF’s Regional Community Workshops are free half-day meetings that allow the IMF to expand the reach of this program to a wider audience. Upcoming Regional Community Workshops will take place in Cleveland, Ohio on March 5, 2016 and in Denver, Colorado on April 2, 2016. The Cleveland workshop features panelists Craig Emmitt Cole, M.D.; Craig Hofmeister, M.D., MPH; and Beth Faiman, PhD, MSN, APRN-BC, AOCN. And the Denver workshop includes the panelists Craig Emmitt Cole, M.D.; Dr. Jeffrey V. Matous, MD; and Sandra Rome, RN, MN, AOCN. Registration is FREE, but seating is limited. To register for either workshop, click HERE.


Share Your Story for Oral Parity Legislation


Due to an outdated design of insurance benefit form, cancer patients across the country are not able to afford their oral anticancer medications. According to Meghan Buzby, the IMF’s Senior Advocacy Director, “patients on oral therapies are being asked to pay a co-insurance for the cost of the drug. They are often being asked to pay upwards of a $1000 per month, per prescription.” If unequal reimbursement has affected you or someone you know, please write a few sentences that tell a personal story. Share your story HERE, and help pass the Cancer Drug Coverage Parity Act of 2015.






Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF InfoLine: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe



 related articles